Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Primary Dysautonomias 1 Polycystic Ovary Syndrome 1 Metabolic Syndrome 1 Insulin Resistance 1 Hyperandrogenism 1

Interventions

Docetaxel 292 Prednisone 241 enzalutamide 195 Leuprolide 185 Radiotherapy 179 Abiraterone Acetate 170 Magnetic Resonance Spectroscopy 163 bicalutamide 141 Goserelin 138 Androgen Antagonists 121 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108 Radiosurgery 108 apalutamide 93 abiraterone 83 gallium 68 PSMA-11 81 Specimen Handling 73 darolutamide 67 Surveys and Questionnaires 64 Gonadotropin-Releasing Hormone 63 Triptorelin Pamoate 58 Radiation 57 Biopsy 57 Brachytherapy 54 cabazitaxel 53 Standard of Care 51 Radiotherapy, Intensity-Modulated 51 Zoledronic Acid 50 pembrolizumab 49 luprolide acetate gel depot 49 Flutamide 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms × Blood Donation × Clear all

NCT04060589 2023-03-22

ReIMAGINE Prostate Cancer Risk

University College, London

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡